BiondVax Pharmaceuticals Stock Price, News & Analysis (NASDAQ:BVXV)

$5.03 0.04 (0.80 %)
(As of 12/18/2017 04:00 PM ET)
Previous Close$4.99
Today's Range$5.01 - $5.06
52-Week Range$3.04 - $10.75
Volume1,800 shs
Average Volume43,593 shs
Market Capitalization$32.87 million
P/E RatioN/A
Dividend YieldN/A
Beta0.33

About BiondVax Pharmaceuticals (NASDAQ:BVXV)

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. Its technology utilizes a combination of conserved epitomes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect. The Company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Debt-to-Equity RatioN/A
Current Ratio26.07%
Quick Ratio26.07%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.97 per share
Price / Book2.55

Profitability

Trailing EPS($1.50)
Net Income$-2,380,000.00
Net MarginsN/A
Return on Equity-66.54%
Return on Assets-48.85%

Miscellaneous

Employees14
Outstanding Shares6,530,000

BiondVax Pharmaceuticals (NASDAQ:BVXV) Frequently Asked Questions

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

When will BiondVax Pharmaceuticals make its next earnings announcement?

BiondVax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for BiondVax Pharmaceuticals.

Who are some of BiondVax Pharmaceuticals' key competitors?

Who are BiondVax Pharmaceuticals' key executives?

BiondVax Pharmaceuticals' management team includes the folowing people:

  • Avner Rotman, Chairman of the Board (Age 74)
  • Ron Babecoff, Chief Executive Officer, President, Director (Age 54)
  • Uri Ben-Or, Chief Financial Officer (Age 47)
  • Tamar Ben-Yedidia, Chief Scientific Officer (Age 53)
  • Yisrael Gewirtz, Internal Auditor (Age 40)
  • George H. Lowell, Director (Age 72)
  • Ori Mor, Director (Age 46)
  • Jack Rosen, Director (Age 71)
  • Irit Ben-Ami, External Director (Age 56)
  • Ruth Ben Yakar, Independent Director (Age 47)

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

Who owns BiondVax Pharmaceuticals stock?

BiondVax Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include NACHT MARIUS (20.56%), EASTERN CAPITAL LTD (7.30%) and IBEX INVESTORS LLC (5.50%). View Institutional Ownership Trends for BiondVax Pharmaceuticals.

How do I buy BiondVax Pharmaceuticals stock?

Shares of BiondVax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BiondVax Pharmaceuticals' stock price today?

One share of BiondVax Pharmaceuticals stock can currently be purchased for approximately $5.03.

How big of a company is BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals has a market capitalization of $32.87 million. The company earns $-2,380,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. BiondVax Pharmaceuticals employs 14 workers across the globe.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]


MarketBeat Community Rating for BiondVax Pharmaceuticals (BVXV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  66
MarketBeat's community ratings are surveys of what our community members think about BiondVax Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BiondVax Pharmaceuticals (NASDAQ:BVXV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

BiondVax Pharmaceuticals (NASDAQ:BVXV) Consensus Price Target History

Price Target History for BiondVax Pharmaceuticals (NASDAQ:BVXV)

BiondVax Pharmaceuticals (NASDAQ:BVXV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
(Data available from 12/18/2015 forward)

Earnings

Earnings History for BiondVax Pharmaceuticals (NASDAQ:BVXV)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

BiondVax Pharmaceuticals (NASDAQ:BVXV) Earnings Estimates

2017 EPS Consensus Estimate: $0.00
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.00$0.00$0.00
Q2 20171$0.00$0.00$0.00
Q3 20171$0.00$0.00$0.00
Q4 20171$0.00$0.00$0.00
(Data provided by Zacks Investment Research)

Dividends

Dividend History for BiondVax Pharmaceuticals (NASDAQ:BVXV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for BiondVax Pharmaceuticals (NASDAQ BVXV)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

BiondVax Pharmaceuticals (NASDAQ BVXV) News Headlines

Source:
DateHeadline
Equities Analysts Offer Predictions for BiondVax Pharmaceuticals Ltd.s FY2017 Earnings (BVXV)Equities Analysts Offer Predictions for BiondVax Pharmaceuticals Ltd.'s FY2017 Earnings (BVXV)
www.americanbankingnews.com - December 15 at 8:32 AM
BiondVax Pharmaceuticals Ltd. Expected to Post Q4 2017 Earnings of $0.00 Per Share (BVXV)BiondVax Pharmaceuticals Ltd. Expected to Post Q4 2017 Earnings of $0.00 Per Share (BVXV)
www.americanbankingnews.com - December 14 at 9:38 AM
BVXV: Planning Continues for M-001 Phase 3 Program …BVXV: Planning Continues for M-001 Phase 3 Program …
finance.yahoo.com - December 12 at 5:21 PM
BiondVax Pharmaceuticals (BVXV) Stock Rating Lowered by ValuEngineBiondVax Pharmaceuticals (BVXV) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 9:26 PM
BiondVax Provides Third Quarter 2017 Financial Results and UpdateBiondVax Provides Third Quarter 2017 Financial Results and Update
finance.yahoo.com - November 28 at 4:55 PM
BiondVax Pharma (BVXV) Reports Clinical Trial Agreement with NIH for U.S. Phase 2 Trial of Universal Flu VaccineBiondVax Pharma (BVXV) Reports Clinical Trial Agreement with NIH for U.S. Phase 2 Trial of Universal Flu Vaccine
www.streetinsider.com - November 21 at 5:01 PM
BiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it BuyBiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it Buy
investorplace.com - November 11 at 4:43 PM
BiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it BuyBiondVax Pharmaceuticals’ (BVXV) Quant Score Makes it Buy
investorplace.com - November 10 at 4:43 PM
BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza VaccineBVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine
finance.yahoo.com - September 20 at 5:35 PM
BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment OptionBiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option
finance.yahoo.com - September 18 at 5:08 PM
BiondVax Pharma (BVXV) Plans Public Offering of ADSsBiondVax Pharma (BVXV) Plans Public Offering of ADSs
www.streetinsider.com - September 14 at 5:32 PM
BiondVax Announces Pricing of Public Offering of American Depositary SharesBiondVax Announces Pricing of Public Offering of American Depositary Shares
finance.yahoo.com - September 13 at 11:04 PM
Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
finance.yahoo.com - September 13 at 6:03 PM
BiondVax Announces Public Offering of American Depositary SharesBiondVax Announces Public Offering of American Depositary Shares
finance.yahoo.com - September 13 at 6:03 PM
BiondVax Provides Second Quarter 2017 Financial Results and UpdateBiondVax Provides Second Quarter 2017 Financial Results and Update
finance.yahoo.com - August 31 at 4:45 PM
Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock ExchangeDual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
finance.yahoo.com - August 31 at 4:45 PM
BiondVax Receives Additional Grant FundingBiondVax Receives Additional Grant Funding
finance.yahoo.com - August 14 at 5:16 PM
BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza VaccineBVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine
finance.yahoo.com - August 1 at 5:38 PM
BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu VaccineBiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine
finance.yahoo.com - July 20 at 6:31 PM
BiondVax Pharma (BVXV) Reports Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu VaccineBiondVax Pharma (BVXV) Reports Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
www.streetinsider.com - July 19 at 6:46 AM
BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu VaccineBiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
finance.yahoo.com - July 18 at 6:21 PM
BVXV: Secures $22 Million Loan Agreement with European Investment Bank…BVXV: Secures $22 Million Loan Agreement with European Investment Bank…
finance.yahoo.com - July 6 at 6:05 PM
BiondVax Pharma (BVXV) Provides H1 General Corporate UpdateBiondVax Pharma (BVXV) Provides H1 General Corporate Update
www.streetinsider.com - June 28 at 9:50 PM
BiondVax Pharmaceuticals (BVXV) Leaps on Israeli NodBiondVax Pharmaceuticals (BVXV) Leaps on Israeli Nod
www.baystreet.ca - March 31 at 9:15 PM
Mid-Morning Market Update: Markets Edge Higher; Lululemon Issues Weak ForecastMid-Morning Market Update: Markets Edge Higher; Lululemon Issues Weak Forecast
www.nasdaq.com - March 30 at 9:31 PM
BiondVax Gets OK to Build Plant in Israel (BVXV)BiondVax Gets OK to Build Plant in Israel (BVXV)
www.investopedia.com - March 30 at 9:31 PM
BiondVax Gets Approval to Build Plant in IsraelBiondVax Gets Approval to Build Plant in Israel
www.investopedia.com - March 30 at 4:29 PM
BiondVax Pharma (BVXV) Publishes Regulatory Approval Strategy for Novel Universal Flu VaccinesBiondVax Pharma (BVXV) Publishes Regulatory Approval Strategy for Novel Universal Flu Vaccines
www.streetinsider.com - March 13 at 12:43 PM
BiondVax Gets $2.8 Mln Investment From Check Point Chairmans Angels High TechBiondVax Gets $2.8 Mln Investment From Check Point Chairman's Angels High Tech
www.nasdaq.com - January 2 at 4:27 PM
BiondVax Announces Third Quarter 2016 Financial Results and UpdateBiondVax Announces Third Quarter 2016 Financial Results and Update
us.rd.yahoo.com - November 30 at 6:31 AM
BiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well ToleratedBiondVax Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate is Safe and Well Tolerated
us.rd.yahoo.com - November 30 at 6:31 AM
7:31 am BiondVax Pharmaceuticals announces positive preliminary safety results from its European Phase 2b clinical trial of M-001, its universal flu vaccine candidate7:31 am BiondVax Pharmaceuticals announces positive preliminary safety results from its European Phase 2b clinical trial of M-001, its universal flu vaccine candidate
us.rd.yahoo.com - November 30 at 6:31 AM
Biondvax Pharma chief investigated for improper use of internal information, released subject to restrictionsBiondvax Pharma chief investigated for improper use of internal information, released subject to restrictions
seekingalpha.com - March 30 at 2:46 PM

SEC Filings

BiondVax Pharmaceuticals (NASDAQ:BVXV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BiondVax Pharmaceuticals (NASDAQ:BVXV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BiondVax Pharmaceuticals (NASDAQ BVXV) Stock Chart for Monday, December, 18, 2017

Loading chart…

This page was last updated on 12/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.